GlaxoSmithKline (NYSE:GSK) is slated to use Owlstone Medical‘s breath biopsy device in a phase II trial of its drug for chronic obstructive pulmonary disease, danirixin.
The diagnostics company’s breathalyzer will be used to help GSK identify which patients will most benefit from the drug, as well as evaluate the effects of danirixin, according to the pharma company.
Get the full story at our sister site, Drug Delivery Business News.
The post GSK to use Owlstone’s breath biopsy device in Phase II COPD trial appeared first on MassDevice.